Fine Vine: Old Dog,...
Health Care: Drugs
Rigel Pharmaceuticals Inc. (RIGL: NASDAQ)
$4.74 -0.11 | -2.27%
05/17/13 - 04:00 PM ET
Portfolios with RIGL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest RIGL Headlines from TheStreet
- Rigel Pharmaceuticals Becomes Oversold (RIGL) 05.03.13 | 04:05 pm
- 5 Health Care Stocks Under $10 Ready to Rip Higher 04.18.13 | 09:04 pm
- 5 Stocks Poised for Breakouts 04.12.13 | 01:04 pm
- Frail Jobs Gains Gives Markets Jitters 04.05.13 | 04:04 pm
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- 3 Stocks Under $10 Making Big Moves 03.15.13 | 07:03 am
- Stocks Under $10: Blossoming Biotech Play
09.25.12 | 06:09 am - The Next Big Thing in Biotech: Pfizer 05.04.12 | 06:05 am
- Biotech Calendar: Key Dates for October 10.03.11 | 08:10 am
- Vertex Arthritis Pill Shines in Mid-Stage Study 09.06.11 | 08:09 am
Press Releases for RIGL
- Rigel Announces Participation At Two Investor Conferences - PR Newswire 02.28.13 | 07:02 am
- Rigel To Present At BIO CEO & Investor Conference - PR Newswire 02.07.13 | 07:02 am
- Rigel To Focus On Extensive Clinical Pipeline At Upcoming J.P. Morgan Presentation - PR Newswire 01.03.13 | 07:01 am
- AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis - PR Newswire 12.13.12 | 07:12 am
- Rigel To Present At Jefferies 2012 Global Healthcare Conference In London - PR Newswire 11.08.12 | 07:11 am
- Rigel Announces Pricing Of Public Offering Of Common Stock - PR Newswire 10.03.12 | 09:10 am
- Rigel Announces Proposed Public Offering Of Common Stock - PR Newswire 10.02.12 | 04:10 pm
- Rigel To Present At UBS Global Life Sciences Conference - PR Newswire 09.17.12 | 07:09 am
- Rigel Initiates Phase 2 Clinical Studies With R343 For Asthma And R333 For Discoid Lupus - PR Newswire 09.05.12 | 07:09 am
- AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma - PR Newswire 06.19.12 | 08:06 am
Partner Headlines for RIGL
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 12.14.12 | 08:12 am
- Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now - Wall St. Cheat Sheet 07.02.12 | 03:07 am
- Rigel Refuels R&D in $130M Offering - Seeking Alpha 05.29.11 | 08:05 am
- CORRECTED - CORRECTED-BRIEF-Rigel earns $25 million from Astrazeneca - Reuters 09.29.10 | 07:09 am
- AstraZeneca signs arthritis drug deal - Financial Times 02.16.10 | 06:02 pm
- Rigel sees partner for psoriasis drug in 3 months - COO - Reuters 02.16.10 | 03:02 pm
